Want to see DMRA full AI Analyst Report?
Top Page
Damora Therapeutics
(NASDAQ:DMRA)
Select Model
Select Model
Rating:47Neutral
Price Target:
$21.50
▼(-25.86% Downside)
Action:Reiterated
Date:09/16/26
The score is primarily held back by weak financial performance (no revenue, ongoing losses, and negative free cash flow despite improved burn) and bearish technicals (price below key moving averages with negative MACD). Valuation is neutral-to-slightly negative due to an uninformative negative P/E and no dividend data.
Positive Factors
Very Low Leverage
Minimal debt reduces solvency and refinancing pressure while preserving financial flexibility. This gives Damora greater capacity to direct available capital toward research and development, and reduces the burden of interest obligations during its pre-revenue stage.
Negative Factors
No Revenue
The absence of revenue means Damora currently lacks operating income to fund research, clinical development, or corporate costs. Until a therapy is commercialized, the business remains dependent on capital resources and successful pipeline progress rather than an established revenue base.
Read all positive and negative factors
Positive Factors
Negative Factors
Very Low Leverage
Minimal debt reduces solvency and refinancing pressure while preserving financial flexibility. This gives Damora greater capacity to direct available capital toward research and development, and reduces the burden of interest obligations during its pre-revenue stage.
Read all positive factors
Damora Therapeutics (DMRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.36B
Dividend YieldN/A
Average Volume (3M)709.47K
Price to Earnings (P/E)―
Beta (1Y)0.08
Revenue GrowthN/A
EPS Growth-850.33%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-122.42
Shares Outstanding61,735,520
10 Day Avg. Volume439,809
30 Day Avg. Volume709,472
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.13
Price to Sales (P/S)0.00
P/FCF Ratio-4.66
Enterprise Value/Market Cap0.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-14.93K
Enterprise Value/Ebitda-4.48
Forecast
1Y Price Target
$46.67Price Target Upside60.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.04
Revenue Forecast (FY)N/A
Damora Therapeutics Business Overview & Revenue Model
Company Description
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that tar...
Damora Therapeutics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -79.00K | 0.00 | -181.00K | -830.00K | -490.00K | -441.00K |
| EBITDA | -263.34M | -209.75M | -21.22M | -37.52M | -61.13M | -51.31M |
| Net Income | -259.69M | -209.84M | -21.44M | -38.35M | -61.62M | -51.75M |
Balance Sheet | ||||||
| Total Assets | 543.64M | 260.53M | 17.13M | 38.23M | 73.19M | 122.22M |
| Cash, Cash Equivalents and Short-Term Investments | 540.51M | 257.62M | 14.18M | 33.15M | 60.22M | 100.19M |
| Total Debt | 0.00 | 68.00K | 1.43M | 249.00K | 804.00K | 847.00K |
| Total Liabilities | 27.58M | 20.15M | 2.66M | 5.90M | 11.44M | 4.99M |
| Stockholders Equity | 516.06M | 240.38M | 14.47M | 32.33M | 61.75M | 117.22M |
Cash Flow | ||||||
| Free Cash Flow | -41.90M | -6.73M | -18.62M | -36.91M | -43.13M | -52.53M |
| Operating Cash Flow | -41.90M | -6.73M | -18.62M | -36.91M | -42.93M | -52.31M |
| Investing Cash Flow | -17.37M | -17.37M | 11.65M | 22.33M | 12.38M | -48.05M |
| Financing Cash Flow | 592.27M | 266.84M | 0.00 | 2.88M | 507.00K | 0.00 |
Damora Therapeutics Technical Analysis
Neutral
29.00
Price Trends
24.12
Negative
25.69
Negative
25.68
Negative
Market Momentum
-0.60
Negative
52.87
Neutral
76.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DMRA, the sentiment is Neutral. The current price of 29 is above the 20-day moving average (MA) of 20.29, above the 50-day MA of 24.12, and above the 200-day MA of 25.68, indicating a neutral trend. The MACD of -0.60 indicates Negative momentum. The RSI at 52.87 is Neutral, neither overbought nor oversold. The STOCH value of 76.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DMRA.
Damora Therapeutics Risk Analysis
Damora Therapeutics disclosed 71 risk factors in its most recent earnings report. Damora Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Damora Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $6.60B | -19.97 | -40.51% | ― | 34.52% | 41.20% | |
63 Neutral | $1.48B | 7.35 | 2515.23% | ― | 92.92% | ― | |
55 Neutral | $2.06B | -14.28 | -72.07% | ― | -69.78% | -106.07% | |
55 Neutral | $1.69B | -7.78 | -59.36% | ― | -86.20% | -476.63% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.70B | -7.82 | -153.12% | ― | ― | ― | |
47 Neutral | $1.36B | -0.18 | -82.56% | ― | ― | -850.33% |
* Healthcare Sector Average
DMRA
Damora Therapeutics
21.96
14.49
193.98%
IOVA
Iovance Biotherapeutics
14.58
12.58
629.00%
ANAB
AnaptysBio
49.63
25.55
106.14%
ZYME
Zymeworks
28.85
9.47
48.86%
STOK
Stoke Therapeutics
26.13
-5.28
-16.81%
GENB
Generate Biomedicines, Inc.
13.21
0.56
4.43%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.